OccuLogix Conducting Rheo Clinical Trial, Crossover Studies Simultaneously
This article was originally published in The Pink Sheet Daily
Executive Summary
OccuLogix' Rheo "dry" age-related macular degeneration therapy pivotal clinical trial enrollment is complete, moving the firm closer to PMA submission. OccuLogix projects device approval in mid-2006.
You may also be interested in...
J&J Sues Boston Scientific, Abbott For $5.5 Bil For Breach Of Contract
After losing bidding war for Guidant, J&J charges winning firms with using leaked information.
State Drug Advertising Laws Foreshadow Future Device Regulation
Some state lawmakers contend that industry's voluntary code of ethics is insufficient, according to Kyphon's chief compliance officer.
FDA Official Distinguishes Scientific Exchange From Off-Label Promotion
Agency compliance head Tim Ulatowski says he's not concerned about the scientific exchange of information on products.